Fundraising Fox
/Companies
Sign in

Nacuity Pharmaceuticals

Fort Worth, US · Founded 2016 · Delaware corporation · 1 known investors

Find your way into Nacuity Pharmaceuticals

Each arrow is one introduction. Sign up to fill in the first one.

143 people can intro you to Michael

Ask Christy Shaffer to introduce you to Michael Wall

You →Christy · together at Nacuity Pharmaceuticals →Michael

51 people can intro you to Jami

Ask Jamie Chen to introduce you to Jami Kern

You →Jamie · together at Nacuity Pharmaceuticals →Jami

Sign up to find every way you can get introduced to Nacuity Pharmaceuticals

  • Your email: who you already know at Nacuity Pharmaceuticals, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nacuity Pharmaceuticals team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Based on the page listing "Ophthalmic Pharmaceutical Consultant" and "Chief Clinical Officer" roles, Nacuity appears to be a pharmaceutical company focused on ophthalmology (eye care), though the page provides insufficient detail to confirm products, customer base, or market focus.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

MWMichael Wall
Michael WallSVP & CSOHe has extensive experience in pharmaceutical development across multiple dosage forms and routes of administration, including solid oral, injectable, topical, and inhalation products, with particular expertise in ophthalmic formulations and regulatory affairs across North American, European, and Asia-Pacific markets.
DWDavid Wohlberg
David WohlbergExecutive
JK
Jami KernSr. Vice President, Chief Clinical OfficerJami Kern is an executive at Nacuity Pharmaceuticals, an ophthalmology-focused pharmaceutical company. Kern has held medical affairs and clinical development roles in the pharmaceutical and medical device sectors.
HCHalden Conner
Halden ConnerCEO/President
CLCharles Lieser
Charles LieserExecutive
CLCarol Lakkis
Carol LakkisDirector/R&D Technical Director

Board

EC
Emmett Cunningham, Jr.Board director
RS
Robin SteeleBoard director
RK
Rusty KelleyBoard director
GC
Gerald CagleBoard director
BY
Benjamin YerxaBoard director

Investors · 1

Funding

SEC filings, press & company announcements

$31.2M disclosed across 4 of 5 rounds · 2016–2025

▶$8.4MraisedDec 2025 · 98 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael WallExecutive Officer
  • Robin SteeleDirector
  • David WohlbergExecutive Officer, Director
  • Rusty KelleyDirector
  • Gerald CagleDirector
  • Jami KernExecutive Officer
  • Benjamin YerxaDirector
  • Emmett Cunningham, Jr.Director
  • Halden ConnerExecutive Officer, Director
  • Charles LieserExecutive Officer
Offering amount
$30M
Amount sold
$8.4M
Minimum investment
$9.4K
Sales commissions
$839.3K
Placement agents
Maxim Group LLC
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.6MraisedJan 2022 · 144 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David WohlbergExecutive Officer, Director
  • Charles LieserExecutive Officer
  • Halden ConnerExecutive Officer, Director
  • Robert RuffoloDirector
  • Robin SteelDirector
  • Benjamin YerxaDirector
  • Gerald CagleDirector
Offering amount
$17.4M
Amount sold
$11.6M
Minimum investment
$10K
Sales commissions
$1.4M
Placement agents
Clifford Adam Teller
First sale
Mar 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.2MraisedJul 2017 · 125 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Isaac BlechDirector
  • Charles LieserExecutive Officer
  • G. Michael Wall, Ph.D.Executive Officer
  • Dr. Gerald D. CagleDirector
  • David J. WohlbergDirector
  • William Halden ConnerExecutive Officer, Director
  • Richard Chin, M.D.Director
  • Sanford HillsbergDirector
Offering amount
$10M
Amount sold
$9.2M
Minimum investment
$25K
Sales commissions
$922.7K
Placement agents
Clifford Adam Teller
First sale
Jun 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedDec 2016 · 46 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William Halden ConnerExecutive Officer, Director
Offering amount
$2.5M
Amount sold
$2M
Minimum investment
$10K
First sale
Nov 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Nacuity Pharmaceuticals went on to found or lead other companies.

Christy ShafferBoard MemberFounded Opus GeneticsEmmett CunninghamMember Board of DirectorsFounded Eyconis

In the news

Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome - BioSpacebiospace.com · Sep 2025Nacuity Pharmaceuticals Raises $16.5M in Series B Financingfinsmes.com · Jun 2022

Frequently asked questions

What does Nacuity Pharmaceuticals do?
Based on the page listing "Ophthalmic Pharmaceutical Consultant" and "Chief Clinical Officer" roles, Nacuity appears to be a pharmaceutical company focused on ophthalmology (eye care), though the page provides insufficient detail to confirm products, customer base, or market focus.
Who are Nacuity Pharmaceuticals's investors?
Nacuity Pharmaceuticals's investors include Tarnagulla Ventures.
How much funding has Nacuity Pharmaceuticals raised?
Nacuity Pharmaceuticals has disclosed $31.2M raised across 4 of its 5 known rounds.
Where is Nacuity Pharmaceuticals headquartered?
Nacuity Pharmaceuticals is headquartered in Fort Worth, US.